Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Development of Rift Valley fever virus candidate vaccines and reagents produced in Nicotiana benthamiana
Rift Valley fever (RVF) is a haemorrhagic fever agent caused by an infection with an enveloped negative-stranded RNA Rift Valley fever virus (RVFV). It belongs to the genus Phlebovirus in the family Bunyaviridae. The virus is spread by infected mosquitoes and affects ruminants and humans, causing hi...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Thesis |
| Language: | English |
| Published: |
Department of Molecular and Cell Biology
2017
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
| _version_ | 1867613643681562624 |
|---|---|
| access_status_str | Open Access |
| author | Mbewana, Sandiswa |
| author2 | Rybicki, Edward P |
| author_browse | Mbewana, Sandiswa Rybicki, Edward P |
| author_facet | Rybicki, Edward P Mbewana, Sandiswa |
| author_sort | Mbewana, Sandiswa |
| collection | Thesis |
| description | Rift Valley fever (RVF) is a haemorrhagic fever agent caused by an infection with an enveloped negative-stranded RNA Rift Valley fever virus (RVFV). It belongs to the genus Phlebovirus in the family Bunyaviridae. The virus is spread by infected mosquitoes and affects ruminants and humans, causing high numbers of neonatal fatalities in animals and occasional fatalities in humans. It is endemic to parts of Africa and the Arabian Peninsula, but is described as an emerging virus due to the wide range of mosquitoes that could spread the disease into non-endemic areas, posing serious health and agricultural problems. The disease can be prevented by vaccination, but there is currently no Food and Drug Administration-approved RVFV vaccine that can be used outside endemic areas, while there are two live attenuated vaccines available for use in endemic areas. These vaccines have the potential for reversion, and are therefore not recommended for use in countries where RVFV is not endemic. This indicates the need for more RVFV vaccine research and development. This work focused on the development of a RVFV vaccine candidate that would allow for differentiation between infected and vaccinated animals as well as humans. |
| format | Thesis |
| id | oai:open.uct.ac.za:11427/25446 |
| institution | University of Cape Town (South Africa) |
| language | eng |
| last_indexed | 2026-06-10T12:39:24.949Z |
| license_str | Not specified — see source repository |
| provenance_str_mv | Harvested via OAI-PMH from UCTD — University of Cape Town Open Access Repository |
| publishDate | 2017 |
| publishDateRange | 2017 |
| publishDateSort | 2017 |
| publisher | Department of Molecular and Cell Biology |
| publisherStr | Department of Molecular and Cell Biology |
| record_format | dspace |
| source_str | UCTD — University of Cape Town Open Access Repository |
| spelling | oai:open.uct.ac.za:11427/25446 Development of Rift Valley fever virus candidate vaccines and reagents produced in Nicotiana benthamiana Mbewana, Sandiswa Rybicki, Edward P Meyers, Ann Molecular and Cell Biology Rift Valley fever (RVF) is a haemorrhagic fever agent caused by an infection with an enveloped negative-stranded RNA Rift Valley fever virus (RVFV). It belongs to the genus Phlebovirus in the family Bunyaviridae. The virus is spread by infected mosquitoes and affects ruminants and humans, causing high numbers of neonatal fatalities in animals and occasional fatalities in humans. It is endemic to parts of Africa and the Arabian Peninsula, but is described as an emerging virus due to the wide range of mosquitoes that could spread the disease into non-endemic areas, posing serious health and agricultural problems. The disease can be prevented by vaccination, but there is currently no Food and Drug Administration-approved RVFV vaccine that can be used outside endemic areas, while there are two live attenuated vaccines available for use in endemic areas. These vaccines have the potential for reversion, and are therefore not recommended for use in countries where RVFV is not endemic. This indicates the need for more RVFV vaccine research and development. This work focused on the development of a RVFV vaccine candidate that would allow for differentiation between infected and vaccinated animals as well as humans. 2017-09-28T05:29:08Z 2017-09-28T05:29:08Z 2017 Doctoral Thesis Doctoral PhD http://hdl.handle.net/11427/25446 eng application/pdf Department of Molecular and Cell Biology Faculty of Science University of Cape Town |
| spellingShingle | Molecular and Cell Biology Mbewana, Sandiswa Development of Rift Valley fever virus candidate vaccines and reagents produced in Nicotiana benthamiana |
| thesis_degree_str | Doctoral |
| title | Development of Rift Valley fever virus candidate vaccines and reagents produced in Nicotiana benthamiana |
| title_full | Development of Rift Valley fever virus candidate vaccines and reagents produced in Nicotiana benthamiana |
| title_fullStr | Development of Rift Valley fever virus candidate vaccines and reagents produced in Nicotiana benthamiana |
| title_full_unstemmed | Development of Rift Valley fever virus candidate vaccines and reagents produced in Nicotiana benthamiana |
| title_short | Development of Rift Valley fever virus candidate vaccines and reagents produced in Nicotiana benthamiana |
| title_sort | development of rift valley fever virus candidate vaccines and reagents produced in nicotiana benthamiana |
| topic | Molecular and Cell Biology |
| url | http://hdl.handle.net/11427/25446 |
| work_keys_str_mv | AT mbewanasandiswa developmentofriftvalleyfeverviruscandidatevaccinesandreagentsproducedinnicotianabenthamiana |